Dr Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, joined Abionyx Pharma in January as new CMO and Head of Research and Development.
Tag Archive for: J&J
Paris-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.